NDC 13985-582 - Acepromazine Maleate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 13985-582
- Package NDCs from labels
- 13985-582-25, 13985-582-50
- Manufacturer
- MWI/VetOne
- Effective date
- 2025-03-17
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Acepromazine Maleate - MWI/VetOne | MWI/VetOne | 2025-03-17 | PRESCRIPTION ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 13985-582-25 | Acepromazine Maleate | 100 in 1 BOTTLE, PLASTIC | TABLET | 100 | 5 | |
| 13985-582-50 | Acepromazine Maleate | 500 in 1 BOTTLE, PLASTIC | TABLET | 500 | 5 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| ACEPROMAZINE MALEATE | ACTIVE INGREDIENT | 37862HP2OM | ACEPROMAZINE MALEATE TABLET [MWI/VETONE] | 1 | |
| ACEPROMAZINE | ACTIVE MOIETY | 54EJ303F0R | ACEPROMAZINE MALEATE TABLET [MWI/VETONE] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 25% Dextrose Infant | 25% DEXTROSE INFANT | HF Acquisition Co. LLC, DBA Health First | 73d04839-a2bb-65dd-e053-2991aa0a82ca | 2022-12-09 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 9c80dfee-8923-4d1f-85b0-98bd68b94212 | 2022-12-07 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Corporation | 50603082-bce5-49eb-9737-e04239cfb695 | 2022-12-07 | Warnings, Adverse reactions | LX22YL083G |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) SOLUTION | Fenwal, Inc. | d55cb701-9664-4931-8754-1a8cae68da06 | 2022-11-01 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE (CPDA-1) SOLUTION | Fenwal, Inc. | f9d7f1b4-7a77-44f9-8924-10b16008b49d | 2022-11-01 | LX22YL083G | |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) | Fenwal, Inc. | 4a08a9ec-46a5-4fcf-80ee-5c33f1a8b746 | 2022-11-01 | LX22YL083G | |
| Dextrose | DEXTROSE MONOHYDRATE | Medical Purchasing Solutions, LLC | 66713d9c-f404-4ec8-e053-2a91aa0a620a | 2022-10-13 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Medical Purchasing Solutions, LLC | 677bb6d6-704b-5be5-e053-2991aa0a5f6f | 2022-10-13 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose Monohydrate | DEXTROSE MONOHYDRATE | Medical Purchasing Solutions, LLC | dc6664a6-1be1-676c-e053-2995a90a3490 | 2022-10-07 | Warnings, Adverse reactions | LX22YL083G |
| ACD Blood-Pack Units (PL 146 PLASTIC) | ANTICOAGULANT CITRATE DEXTROSE (ACD) | Fenwal, Inc. | ba894daa-688e-4a9e-bd74-e71797f951bb | 2022-04-27 | LX22YL083G | |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | LX22YL083G | |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 0bfb32b2-d034-4219-a055-3448f0c424f7 | 2021-02-19 | Warnings, Adverse reactions | LX22YL083G |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | LX22YL083G | |
| LACTATED RINGERS AND DEXTROSE | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | HF Acquisition Co LLC, DBA HealthFirst | a62cf623-9b8a-37e0-e053-2995a90add5b | 2020-05-21 | Warnings, Adverse reactions | LX22YL083G |
| DEXTROSE AND SODIUM CHLORIDE | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE | Fresenius Kabi USA, LLC | b825c9c4-f2fb-4a4a-9d8c-fb020ad07e93 | 2020-04-30 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e | 2020-02-27 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | LX22YL083G |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.